
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc. is positioned favorably in the biopharmaceutical sector through its innovative approach to developing targeted therapies for autoimmune disorders, utilizing a proprietary precision data analytics platform and leading expertise. The company's pipeline includes promising candidates such as envudeucitinib (envu), which has shown superior efficacy compared to competitors in early-stage trials, potentially establishing its dominance within the TYK2 inhibitor class. Additionally, Alumis has a strong focus on cost management, which positions it well for future financial success as the market for next-generation therapies continues to grow.
Bears say
Alumis Inc faces a negative outlook primarily due to significant risks associated with its lead pipeline candidates, specifically the inability to advance ESK-001 into pivotal trials on schedule and potential failures in demonstrating compelling efficacy in psoriasis and systemic lupus erythematosus. Additionally, the company's valuation at approximately $730 million appears disconnected from the heightened likelihood of competitive pressures and delays in regulatory approvals, which could hinder market uptake. Furthermore, ongoing concerns about possible dilution risks and overall competitive dynamics in the immunology and inflammation space further exacerbate the uncertainty surrounding Alumis's commercial prospects.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares